Norganoid

Norganoid is a private, pre-revenue platform company founded in 2019 and headquartered in Cambridge, UK, with a significant operational presence in Graz, Austria. The company is developing an integrated platform, featuring its OrganCore™ plug-and-play OoC system and AI-driven analytics, to automate and scale the production and analysis of human organoids for drug safety and efficacy testing. By replacing traditional 2D cell cultures and animal models with more human-relevant systems, Norganoid targets the growing market for New Approach Methodologies (NAMs) in pharmaceutical R&D, aiming to reduce clinical trial attrition rates and advance personalized medicine.

Integrated platform combining the OrganCore™ plug-and-play organ-on-a-chip system for automated iPSC differentiation and 3D organoid culture with AI-driven computer vision for phenotypic analysis and drug screening.

Norganoid competes in a crowded and rapidly evolving space that includes well-funded OoC companies (e.g., Emulate, Mimetas), large life science tool providers (e.g., Merck, Thermo Fisher), and numerous startups focusing on organoids, microfluidics, or AI-driven biology. Differentiation hinges on the seamless integration and automation of the entire workflow from stem cell to data output.